In particular, adding trastuzumab, a recombinant humanized monoclonal antibody directed against the ectodomain of the receptor tyrosine kinase ERBB2, to regimens containing existing chemotherapeutic agents has significantly improved clinical outcomes for breast cancer patients. Here, ERBB2 is linked to breast cancer.